-

01:28:32 AM

LIVE Real Time OPGN Stock Market News

OPGN - Opgen Inc

04/19/21 7:30 AM

Nasdaq : OPGN

OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections

Collaboration with NYS Department of Health's Wadsworth Center continues for extended six-month term until September 30, 2021 Project utilizes OpGen's Acuitas(R) AMR Gene Panel and Acuitas Lighthouse(R) Software within digital health and precision medicine platform at multiple healthcare institutions

RHEA-AI

very positive

04/12/21 7:30 AM

Nasdaq : OPGN

OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients

Experts presented the results of their Unyvero studies and demonstrated: Distinguishing those COVID-19 ICU patients with bacterial superinfection early and accurately is crucial for patient management and antibiotic stewardship Unyvero detected bacterial pathogens up to 7 days earlier and would

RHEA-AI

neutral

03/25/21 4:01 PM

Nasdaq : OPGN

OpGen Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Total combined pro-forma revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.4 million cash as of December 31, 2020 Raised an additional $34.7 million of capital in the first quarter of 2021 Conference call to be held at 4:30 p.m. Eastern Time today

RHEA-AI

positive

03/11/21 7:30 AM

Nasdaq : OPGN

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020

OpGen, Inc. (NASDAQ: OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Thursday,

RHEA-AI

neutral

03/08/21 7:30 AM

Nasdaq : OPGN

OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia

Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients High negative predictive value of 99.8% may allow for reduction in unnecessary antibiotic use and support antibiotic

RHEA-AI

neutral

03/01/21 7:30 AM

Nasdaq : OPGN

OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System

Chinese regulatory authority NMPA completes registration of Unyvero instrument system as IVD for Chinese market Application of Unyvero cartridge for pneumonia is under review and pending NMPA approval OpGen's subsidiary Curetis and its Chinese partner Beijing Clear Biotech continue working with the

RHEA-AI

very positive

02/16/21 7:30 AM

Nasdaq : OPGN

OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing

Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data Publication supports harmonization of the development of good machine learning practices as encouraged in recent FDA AI/ML Software as a Medical Device Action Plan Work

RHEA-AI

positive

02/09/21 8:30 AM

Nasdaq : OPGN

OpGen, Inc. Announces $25 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

OpGen, Inc. (Nasdaq: OPGN, "OpGen"), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced it has entered into a definitive agreement with a single U.S.-

RHEA-AI

neutral

01/13/21 7:30 AM

Nasdaq : OPGN

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update

Preliminary total pro-forma combined revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.3 million cash as of December 31, 2020 and total capital raised in 2020 of $35.3 million OpGen subsidiary Ares Genetics to explore multiple collaboration opportunities with

RHEA-AI

positive

01/05/21 7:30 AM

Nasdaq : OPGN

OpGen Subsidiary Curetis and Annar Enter into Unyvero Distribution Partnership for Colombia

RHEA-AI

positive